阿爾茨海默病與2型糖尿病

1、阿爾茨海默病與2型糖尿病的關(guān)系及相關(guān)藥物研究進展東南大學2011級焦嬌論文報告會大綱論文報告會01 02 03 04介紹 相關(guān)研究 藥物研究 總結(jié)0101論文報告會介紹阿爾茨海默?。ˋlzheimers Disease, AD）2型糖尿病（Type 2 Diabetes Mellitus, T2D）4680萬DM 3.82億標準化患病率6.61%DM患病率11.6%,T2D占90%02 神經(jīng)病理學特征：1. 淀粉樣蛋白沉積造成的老年斑（senile plaque，SP）2. 過磷酸化tau蛋白形成的神經(jīng)纖維纏結(jié)（neurofiberilary tangles, NFT）6,7論文報告會大綱論文

2、報告會01 02 03 04介紹 相關(guān)研究 藥物研究 總結(jié)0203論文報告會相關(guān)研究04流行病學研究分子機制研究研究名稱研究名稱年份年份火奴魯魯-亞洲老年隊列2006PROSPER隊列2010ACCORD-MIND研究2014T2D是AD發(fā)病的危險因素010302糖代謝紊亂糖代謝紊亂血管因素血管因素胰島素通胰島素通路受損路受損分子機制研究01 葡萄糖轉(zhuǎn)運體(Glucose Transporter, GLUT)減少 糖基化終末產(chǎn)物( Advanced Glycation End Products, AGEs)增多 血腦屏障血腦屏障（Blood Brain Barrier, BBB）破壞破壞 腦血

3、流量腦血流量（Cerebral Blood Flow, CBF） 糖攝取糖攝取 BBB對對A清除率清除率 神經(jīng)元功能神經(jīng)元功能障礙障礙 蛋白質(zhì)沉積蛋白質(zhì)沉積 氧化應(yīng)激氧化應(yīng)激 誘導誘導炎癥反應(yīng)炎癥反應(yīng) 調(diào)節(jié)調(diào)節(jié)細胞周期細胞周期 RAGE結(jié)合結(jié)合AA入腦入腦02胰島素抵抗03 GLUT 微血管病變論文報告會外周腦內(nèi)血腦屏障血腦屏障葡萄糖葡萄糖炎癥因子炎癥因子炎癥因子炎癥因子TNF-, IL1-, IL-6神經(jīng)細胞神經(jīng)細胞胰島素抵抗胰島素抵抗胰島素胰島素受體（受體（IR）線粒體線粒體ROSAGEsAAGE受體受體（RAGE）A胰島素胰島素競競爭爭05外周外周腦內(nèi)腦內(nèi)惡性循環(huán)認知障礙論文報告會細胞外

4、細胞內(nèi)06細胞膜細胞膜GLUT1/3葡萄糖葡萄糖IR胰島素胰島素IRSPI3KPIP2PIP3MAPKGSK-3認知障礙認知障礙HBPUDP-GlcNacTau蛋白蛋白PPPGGGUDP(Tau蛋白蛋白GGGGGGPPPPPPNFTsA論文報告會大綱論文報告會01 02 03 04介紹 相關(guān)研究 藥物 總結(jié)0307論文報告會藥物研究08治療糖尿病藥物治療糖尿病藥物共同作用靶點藥共同作用靶點藥二甲雙胍二甲雙胍？胰島素胰島素胰高血糖素樣肽胰高血糖素樣肽-1二肽基肽酶抑制劑二肽基肽酶抑制劑-4噻唑烷二酮類噻唑烷二酮類胰島淀粉樣多肽胰島淀粉樣多肽磺酰脲類磺酰脲類非磺酰尿類促泌劑非磺酰尿類促泌劑瘦素瘦素

5、論文報告會大綱論文報告會01 02 03 04介紹 相關(guān)研究 藥物研究 總結(jié)0409論文報告會總結(jié)ADT2D 疾病特點疾病特點 發(fā)病機制發(fā)病機制ADT2D糖代謝紊亂胰島素通路受損血管損傷AD胰島素胰島素胰高血糖素樣肽胰高血糖素樣肽-1噻唑烷二酮類噻唑烷二酮類懇請指正！論文報告會參考文獻 1.World Alzheimer Report 2015: The Global Impact of Dementia | Alzheimers Disease International. 2016. 2.Jia, J., et al., The prevalence of dementia in urba

6、n and rural areas of China. Alzheimers & Dementia, 2014. 10(1): p. 1-9. 3.Guariguata, L., et al., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 103(2): p. 137-149. 4.Xu, Y., et al., PRevalence and control of diabetes in chinese ad

7、ults. JAMA, 2013. 310(9): p. 948-959. 5.GBD, M.A.C.O., Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014. 385(9963): p. 117-171.6.Ballard, C., et a

8、l., Alzheimers disease. The Lancet. 377(9770): p. 1019-1031. 7.劉曉燕與張志珺, Tau蛋白在阿爾茨海默病中的研究進展. 中華腦血管病雜志(電子版), 2011(05): 第411-416頁. 8.Fjell, A.M., et al., What is normal in normal aging? Effects of aging, amyloid and Alzheimers disease on the cerebral cortex and the hippocampus. Progress in Neurobiology

9、, 2014. 117: p. 20-40. 9.Korf, E.S.C., et al., Brain Aging in Very Old Men With Type 2 Diabetes: The Honolulu-Asia Aging Study. Diabetes Care, 2006. 29(10): p. 2268 -2274.論文報告會參考文獻 10.van Elderen, S.G., et al., Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-

10、up. Neurology, 2010. 75(11): p. 997-1002.11.Profenno, L.A., A.P. Porsteinsson and S.V. Faraone, Meta-Analysis of Alzheimers Disease Risk with Obesity, Diabetes, and Related Disorders. Biological Psychiatry, 2010. 67(6): p. 505-512.12.Gudala, K., et al., Diabetes mellitus and risk of dementia: A meta

11、 analysis of prospective observational studies. Journal of Diabetes Investigation, 2013. 4(6): p. 640-650.13.Sims-Robinson, C., et al., How does diabetes accelerate Alzheimer disease pathology? Nature reviews. Neurology, 2010. 6(10): p. 551-559.14.Erus, G., et al., Spatial Patterns of Structural Bra

12、in Changes in Type 2 Diabetic Patients and Their Longitudinal Progression With Intensive Control of Blood Glucose. Diabetes Care, 2014. 38(1): p. 97-104.15.Moran, C., et al., Brain Atrophy in Type 2 Diabetes: Regional distribution and influence on cognition. Diabetes Care, 2013. 36(12): p. 4036-4042

13、.16.Yang, S., et al., Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Progress in Neurobiology.17.Gray, S.M., R.I. Meijer and E.J. Barrett, Insulin Regulates Brain Function, but How Does It Get There? Diabetes

14、, 2014. 63(12): p. 3992-3997.論文報告會參考文獻18.de la Monte, S.M., Type 3 Diabetes is Sporadic Alzheimers disease: Mini-Review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014. 24(12): p. 1954-1960.19.Simpson, I.A., et al., Decreased concentrations of

15、 GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimers disease. Ann Neurol, 1994. 35(5): p. 546-51.20.Kalaria, R.N. and S.I. Harik, Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimers disease. Prog Clin Biol Res, 1989. 317: p. 415-2

16、1.21.Winkler, E.A., et al., GLUT1 reductions exacerbate Alzheimers disease vasculoneuronal dysfunction and degeneration. Nature neuroscience, 2015. 18(4): p. 521-530.22.Liu, Y., et al., Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS letter

17、s, 2008. 582(2): p. 359-364.23.Liu, Y., et al., Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer disease. Journal of neurochemistry, 2009. 111(1): p. 242-249.24.Jin, N., et al., CREB regulates the expression of neuronal glucose transporter 3: a possibl

18、e mechanism related to impaired brain glucose uptake in Alzheimers disease. Nucleic Acids Research, 2013. 41(5): p. 3240-3256.25.Correia, S.C., et al., Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimers disease and diabetes interrelation. Brain Research, 2012. 1441:

19、p. 64-78.26.Srikanth, V., et al., Advanced glycation endproducts and their receptor RAGE in Alzheimers disease. Neurobiology of Aging, 2011. 32(5): p. 763-777.論文報告會參考文獻27.Kuhla, A., et al., Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimers

20、disease brain. Neurobiology of Aging, 2015. 36(2): p. 753-761.28.More, S.S., A.P. Vartak and R. Vince, Restoration of Glyoxalase Enzyme Activity Precludes Cognitive Dysfunction in a Mouse Model of Alzheimers Disease. ACS Chemical Neuroscience, 2012. 4(2): p. 330-338.29.de la Monte, S.M. and M. Tong,

21、 Brain metabolic dysfunction at the core of Alzheimers disease. Biochemical Pharmacology, 2014. 88(4): p. 548-559.30.De Felice, F.G., Alzheimers disease and insulin resistance: translating basic science into clinical applications. The Journal of Clinical Investigation, 2013. 123(2): p. 531-539.31.Di

22、neley, K.T., J.B. Jahrling and L. Denner, Insulin resistance in Alzheimers disease. Neurobiology of Disease, 2014. 72, Part A: p. 92-103.32.Garcia-Casares, N., et al., Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. J Alzheimers Dis, 2014. 40

23、(2): p. 375-86.33.Baker, L.D., et al., Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol, 2011. 68(1): p. 51-7.34.Willette, A.A., et al., Association of Insulin Resistance With

24、 Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA Neurol, 2015. 72(9): p. 1013-20.論文報告會參考文獻35.Ishibashi, K., et al., Reduced uptake of 18F-FDG and 15O-H2O in Alzheimers disease-related regions after glucose loading. J Cereb Blood Flow Metab, 2015. 35(8): p. 1380

25、-5.36.Ishibashi, K., et al., Relationship Between Alzheimer DiseaseLike Pattern of 18F-FDG and Fasting Plasma Glucose Levels in Cognitively Normal Volunteers. Journal of Nuclear Medicine, 2015. 56(2): p. 229 -233.37.Ishibashi, K., et al., Plasma Glucose Levels Affect Cerebral 18F-FDG Distribution in

26、 Cognitively Normal Subjects With Diabetes. Clin Nucl Med, 2016.38.Calvo-Ochoa, E. and C. Arias, Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimers disease: studies in animal models.

27、 Diabetes/Metabolism Research and Reviews, 2015. 31(1): p. 1-13.39.Deng, Y., et al., Dysregulation of Insulin Signaling, Glucose Transporters, O-GlcNAcylation, and Phosphorylation of Tau and Neurofilaments in the Brain : Implication for Alzheimers Disease. The American Journal of Pathology, 2009. 17

28、5(5): p. 2089-2098.40.Kadavath, H., et al., Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A, 2015. 112(24): p. 7501-6.41.Frost, B., J. Gtz and M.B. Feany, Connecting the dots between tau dysfunction and neurodegeneration. Trends in Cell

29、Biology. 25(1): p. 46-53.42.劉曉燕與張志珺, Tau蛋白在阿爾茨海默病中的研究進展. 中華腦血管病雜志(電子版), 2011(05).論文報告會參考文獻43.Selkoe, D.J., Alzheimers Disease: Genes, Proteins, and Therapy. Physiological Reviews, 2001. 81(2): p. 741-766.44.Salahuddin, P., et al., Structure of amyloid oligomers and their mechanisms of toxicities: Ta

30、rgeting amyloid oligomers using novel therapeutic approaches. Eur J Med Chem, 2016. 114: p. 41-58.45.Ma, L., J. Wang and Y. Li, Insulin resistance and cognitive dysfunction. Clinica Chimica Acta, 2015. 444: p. 18-23.46.Zhang, H., et al., Intranasal Insulin Enhanced Resting-State Functional Connectiv

31、ity of Hippocampal Regions in Type 2 Diabetes. Diabetes, 2014. 64(3): p. 1025-1034.47.Thambisetty, M., et al., Impaired Glucose Tolerance in Midlife and Longitudinal Changes in Brain Function During Aging. Neurobiology of aging, 2013. 34(10): p. 2271-2276.48.Traumatic Brain Injury, Microglia, and Be

32、ta Amyloid. International Journal of Alzheimers Disease, 2012. 2012: p. 5.49.Hort, J., et al., EFNS guidelines for the diagnosis and management of Alzheimers disease. 2010, Blackwell Publishing Ltd. p. 1236-1248.50.Schmidt, R., et al., EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhi

33、bitors and memantine in moderate to severe Alzheimers disease. 2015. p. 889-898.51.張志珺, 王.A.任.A., SSRI類抗抑郁劑在阿爾茨海默病中的應(yīng)用研究進展. 東南大學學報(醫(yī)學版), 2014(04): 第504-508頁.論文報告會參考文獻52.Yu, Y., et al., Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.

34、Journal of Neural Transmission, 2014. 122(4): p. 593-606.53.Freiherr, J., et al., Intranasal Insulin as a Treatment for Alzheimers Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 2013. 27(7): p. 505-514.54.徐小惠與張志珺, 脂質(zhì)代謝通路候選基因與阿爾茨海默病關(guān)系的研究進展. 中華腦血管病雜志(電子版), 2012(02).55.Ma, J., et

35、 al., Amyloid-associated proteins alpha1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. 1994. 372(6501): p. 92-94.56.Yarchoan, M. and S.E. Arnold, Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. Diabetes, 2014. 63(7): p.

36、 2253-2261.57.Morris, J.K. and J.M. Burns, Insulin: An Emerging Treatment for Alzheimers Disease Dementia? Current neurology and neuroscience reports, 2012. 12(5): p. 520-527.58.McClean, P.L. and C. Holscher, Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP

37、/PS1 mice, a model of Alzheimers disease. Neuropharmacology, 2014. 76 Pt A: p. 57-67.59.Garcia-Casares, N., et al., Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimers disease?. Rev Neurol, 2014. 59(11): p. 517-24.論文報告會參考文獻60.McClean, P.L. and C. Holscher, Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimers disease. Neur